Search company, investor...

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

Founded Year



Series B | Alive

Total Raised


Last Raised

$20.36M | 3 yrs ago

About MediSix Therapeutics

MediSix Therapeutics is a Singapore-based immune engineering company developing cellular therapies to address T cell malignancies.

MediSix Therapeutics Headquarters Location

11 Biopolis Way #05-08/09 Helios



Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing MediSix Therapeutics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

MediSix Therapeutics is included in 3 Expert Collections, including Biopharma Tech.


Biopharma Tech

5,241 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.


Regenerative Medicine

1,818 items

Regenerative medicine refers to the process of activating, replacing, engineering or regenerating human genetic material, cells, tissues or organs to restore normal function. It also includes bioengineered tissues used for in vitro testing (e.g. organ-on-a-chip, organoids).



3,605 items

Companies researching, developing, or offering products & services that aid in the screening, prevention, diagnosis, management, and treatment of cancer.

MediSix Therapeutics Patents

MediSix Therapeutics has filed 2 patents.

The 3 most popular patent topics include:

  • Clusters of differentiation
  • Immune system
  • Immunology
patents chart

Application Date

Grant Date


Related Topics



Olfactory receptors, Clusters of differentiation, Immunology, Immune system, Transcription factors


Application Date


Grant Date


Related Topics

Olfactory receptors, Clusters of differentiation, Immunology, Immune system, Transcription factors



Latest MediSix Therapeutics News

Twist and MediSix link up on T-cell therapies development

Apr 8, 2022

Twist Bioscience (Nasdaq: TWST) and MediSix Therapeutics have announced a collaboration to discover novel antibodies against five undisclosed targets. Under the terms of the collaboration, Twist will leverage its proprietary Library of Libraries to discover five novel antibodies directed against MediSix’s targets. MediSix will use its unique platform technologies to develop novel CAR T-cell therapies targeting malignancies and autoimmune… This article is accessible to registered users, to continue reading please register for free . A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please  login . If your trial has come to an end, you can  subscribe here. • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech. • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results. • Daily roundup of key events in pharma and biotech. • Monthly in-depth briefings on Boardroom appointments and M&A news. • Choose from a cost-effective annual package or a flexible monthly subscription. If you are already a registered user please login . The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed Chairman, Sanofi Aventis UK

MediSix Therapeutics Web Traffic

Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

MediSix Therapeutics Rank

  • When was MediSix Therapeutics founded?

    MediSix Therapeutics was founded in 2016.

  • What is MediSix Therapeutics's latest funding round?

    MediSix Therapeutics's latest funding round is Series B.

  • How much did MediSix Therapeutics raise?

    MediSix Therapeutics raised a total of $40.36M.

  • Who are the investors of MediSix Therapeutics?

    Investors of MediSix Therapeutics include Lightstone Ventures, Osage University Partners, Three Arch Partners and Temasek.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.